伊伐布雷定通过调控TIMP-1表达对冠心病大鼠抗心肌纤维化和心肌保护作用的机制
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:

国家重点研发计划项目(2017YFC1700503)


Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    目的 研究伊伐布雷定(Ivabradine)对冠心病大鼠心肌纤维化和心肌损伤的影响及其机制。方法 60只SD大鼠随机分为对照组、模型组和伊伐布雷定低、高剂量组,每组15只。除对照组外,其他3组大鼠通过高脂饲料喂养联合注射维生素 D3构建冠心病模型,造模成功后伊伐布雷定低、高剂量组大鼠分别按照10 mg/kg、20 mg/kg的伊伐布雷定灌胃给药,每日1次,连续给药4 周。超声成像系统检测大鼠心功能,酶联免疫分析仪测定丙二醛(MDA)、超氧化物岐化酶(SOD)和脑钠肽(BNP)水平,苏木精伊红染色(HE)检测大鼠主动脉弓和心肌组织病理学变化,Masson 染色检测心肌组织胶原纤维表达,免疫组化染色检测心肌组织金属蛋白酶组织抑制因子1(TIMP-1)、Ⅰ型胶原(collagen-Ⅰ)、Ⅲ型胶原(collagen Ⅲ)的表达,Western blot检测心肌组织TIMP-1、Cleaved-Caspase3、Bcl-2、Bax蛋白表达水平。 结果 与对照组比较,模型组大鼠EF和FS下降,LVDD和LVSD增加(P<0.05);血清MDA浓度升高,SOD活性降低,BNP水平升高(P<0.05);主动脉中斑块面积比例增加,心肌纤维排列紊乱,心肌细胞出现肥大、变性和坏死等病变现象,并有大量蓝色胶原纤维;心肌组织TIMP-1、collagen-Ⅰ和collagen Ⅲ阳性表达率增加(P<0.05),同时TIMP-1、CleavedCaspase3和Bax蛋白相对表达量升高,Bcl-2蛋白相对表达量下降(P<0.05)。与模型组比较,伊伐布雷定低、高剂量组大鼠EF和FS升高,LVDD和LVSD减小(P<0.05);MDA浓度降低,SOD活性升高,而BNP水平降低(P<0.05);主动脉中斑块面积比例减少,心肌组织病变得到明显的改善,有少量的蓝色胶原纤维;心肌组织TIMP-1、collagen Ⅰ和collagen Ⅲ阳性表达率减少(P<0.05),同时TIMP-1、CleavedCaspase3和Bax蛋白相对表达量下降,Bcl-2蛋白相对表达量升高(P<0.05)。结论 伊伐布雷定可能具有保护冠心病大鼠心肌组织和减轻心肌纤维化的作用。

    Abstract:

    Objective To observe the effect and mechanism of ivabradine on myocardial fibrosis and myocardial injury in rats with coronary heart disease. Methods 60 SD rats were randomly divided into control group, model group and ivabradine low and high dose groups, 15 rats in each group. In addition to the control group, the other three groups of rats were fed with high-fat diet and injected with vitamin D3 to build a coronary heart disease model. After successful modeling, the rats in the lowdose and high-dose ivabradine group were administered by intragastric administration of ivabradine at 10 mg/kg and 20 mg/kg, once a day for 4 weeks. Ultrasound imaging system detects rat heart function. Enzyme linked immunoassay analyzer was used to measure the levels of malondialdehyde (MDA), superoxide dismutase (SOD) and brain natriuretic peptide (BNP). Hematoxylineosin staining (HE) was used to detect histopathological changes of rat aortic arch and myocardium. Masson staining was used to detect the expression of collagen fibers in myocardial tissue. 〖JP2〗Immunohistochemical staining was used to detect the expression of tissue inhibitor of metalloproteinase-1 (TIMP-1), collagen-Ⅰ,collagen Ⅲ. Western blot was used to detect the protein expression levels of TIMP-1, ClearedCaspase3, Bcl2 and Bax in myocardial tissue. Results Compared with the control group, the model group EF and FS decreased, LVDD and LVSD increased (P<0.05), Serum MDA concentration increased, SOD activity decreased, BNP level increased(P<0.05), proportion of plaque area in the aorta increased, the arrangement of myocardial fibers disordered, and myocardial cells appeared hypertrophy, degeneration and necrosis, and there are a lot of blue collagen fibers. The positive expression rate of TIMP1, collagen Ⅰ and collagen Ⅲ in myocardial tissue increased (P<0.05). At the same time, the relative expression of TIMP-1, ClearedCaspase3 and Bax protein increased, and the relative expression of Bcl-2 protein decreased (P<0.05). Compared with the model group, the EF and FS of rats in the lowdose and highdose ivabradine group increased, LVDD and LVSD decreased (P<0.05), MDA concentration decreased, SOD activity increasedand BNP level decreased (P<0.05), the proportion of plaque area in the aorta ; decreased, Myocardial tissue lesions significantly improved, with a small amount of blue collagen fibers; myocardial tissue TIMP-1, collagen Ⅰand collagen Ⅲ positive expression rate decreased (P<0.05). At the same time, the relative expression of TIMP-1, ClearedCaspase3 and Bax protein decreased, and the relative expression of Bcl-2 protein increased (P<0.05). ConclusionIvabradine may have a protective effect on myocardial tissue and alleviate myocardial fibrosis in rats with coronary heart disease.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-08-24
您是第位访问者
网站版权所有:《西部医学》编辑部     蜀ICP备18038379号-4
地址:四川省成都市武侯区小天竺街75号财富国际18F-1号    邮政编码:610041
电话:028-85570072/85588403 本网站支持 IPv6    E-mail:xbyxqk@163.com
技术支持:北京勤云科技发展有限公司